Advisory Committee Votes in Favor of Positive Benefit/Risk Profile for Belantamab Mafodotin in R/R...
The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted 12-0 in favor of positive...
Changing Strategies in the War on Cancer, Part 3
Over the last 25 years, there has been an explosion of new and vitally important, anticancer drugs.
The development of...
Changing Strategies in the War on Cancer, Part 2
For decades, the hallmark of medical treatment for cancer and hematological malignancies has been intravenous cytotoxic chemotherapy. These drugs...
Changing Strategies in the War on Cancer, Part 1
The National Cancer Act signed in 1971 officially started what is commonly referred to as the “war against cancer.”
Since...
